(CNN) – Pfizer and BioNTech said Thursday that they are requesting emergency use authorization from the US Food and Drug Administration for their COVID-19 vaccine for children ages 5 to 11.
If authorized, this would be the first COVID-19 vaccine for younger children. The Pfizer / BioNTech vaccine is approved for persons 16 years of age and older and has an emergency use authorization for persons 12-15 years of age.
Last month, Pfizer released details of a phase 2/3 trial that showed its COVID-19 vaccine was safe and elicited a “robust” antibody response in children ages 5 to 11. The trial included 2,268 participants aged 5 to 11 years and used a two-dose regimen of the vaccine given 21 days apart. This trial used a 10-microgram dose, lower than the 30-microgram dose that has been used for those over 12 years of age.
Participants’ immune responses were measured by looking at the levels of neutralizing antibodies in their blood and comparing those levels with a control group of people aged 16 to 25 who received a two-dose regimen with the larger 30-microgram dose. Pfizer said the levels compare well to those of older people who received the higher dose, demonstrating a “strong immune response in this cohort of children one month after the second dose.”
Pfizer began submitting the data to the FDA late last month, but has not formally requested authorization so far.
FDA officials had said that once the vaccine data for younger children were submitted, the agency could authorize a vaccine for younger children in a matter of weeks, not months, but it would depend on the timing and quality of the shots. data provided.
In anticipation of the request, the FDA scheduled a meeting of its Advisory Committee on Vaccines and Related Biologics to discuss the vaccine in children ages 5 to 11 on October 26. If approved by the FDA, a CDC vaccine advisory panel will meet to consider whether to recommend its use.
“We know from our vast experience with other pediatric vaccines that children are not young adults, and we will conduct a comprehensive evaluation of the clinical trial data presented to support the safety and efficacy of the vaccine used in a younger pediatric population, which may need a different dosage or formulation than that used in an elderly pediatric population or in adults, ”said Acting FDA Commissioner Dr. Janet Woodcock in a statement regarding the October 26 meeting.
https://wakelet.com/wake/TGGlJ6fzdGn_d44ce4kIw
https://wakelet.com/wake/dFWvnKzyhSF6Sa_Sa6RK0
https://wakelet.com/wake/lH14aLwEIsYKOvjdwvJc0
https://wakelet.com/wake/teWy8r5UAWf-e38KQokKT
https://wakelet.com/wake/WZhVrZKu1HKGa4NbpZ4vc
https://wakelet.com/wake/13EJfLSS9yHLWjfaAr0Kr
https://wakelet.com/wake/UB9jiDt39xV8jVMHrc-n_
https://wakelet.com/wake/yMSEMhB1yZ0t5W559Jna9
https://wakelet.com/wake/zBLJjTsJGSW5mYYsu7llj
https://wakelet.com/wake/Gmlr0YeTHgyejLPZNucWd
https://wakelet.com/wake/jCMWpeSitKBnTmrAAOx6e
https://wakelet.com/wake/pArXOEkgeKNupDcdw-L0p
https://wakelet.com/wake/JMA5cPkyHOj8RmdSTc_Hr
https://wakelet.com/wake/fzKM8o9HjtRyOSiVuL6O8
https://wakelet.com/wake/hyz380oHnDA35CcpR-BYs
https://wakelet.com/wake/GTubTFIFCQeDEKIPrRAK9
https://wakelet.com/wake/6qmP0iq_E0nuzpJknIDHy
https://wakelet.com/wake/SdxQ5QDx64ulJ4cpy-dOA
https://wakelet.com/wake/2sVgeHM-L9rkShOQ1jm_j
https://wakelet.com/wake/9yLsJb9g3gmaEdgnrycLk
https://wakelet.com/wake/NK5y-mrRNLW1kfAm3zDT7
https://wakelet.com/wake/Syq4HpCGnv-M1XTpw0bOr
https://wakelet.com/wake/quyJ7HcfmxoWOm6_NwJKv
https://wakelet.com/wake/jPDon7yEBF8IWuKT_mOiI
https://wakelet.com/wake/tpctNQ1BhHnmOdy4mEBFA